Rights statement: The final, definitive version of this article has been published in the Journal, Statistical Methods in Medical Research, ? (?), 2019, © SAGE Publications Ltd, 2019 by SAGE Publications Ltd at the Statistical Methods in Medical Research page: https://journals.sagepub.com/home/smm on SAGE Journals Online: http://journals.sagepub.com/
Accepted author manuscript, 470 KB, PDF document
Available under license: CC BY-NC: Creative Commons Attribution-NonCommercial 4.0 International License
Final published version
Research output: Contribution to Journal/Magazine › Journal article › peer-review
Research output: Contribution to Journal/Magazine › Journal article › peer-review
}
TY - JOUR
T1 - A robust Bayesian meta-analytic approach to incorporate animal data into phase I oncology trials
AU - Zheng, Haiyan
AU - Hampson, Lisa Victoria
AU - Wandel, Simon
N1 - The final, definitive version of this article has been published in the Journal, Statistical Methods in Medical Research, ? (?), 2019, © SAGE Publications Ltd, 2019 by SAGE Publications Ltd at the Statistical Methods in Medical Research page: https://journals.sagepub.com/home/smm on SAGE Journals Online: http://journals.sagepub.com/
PY - 2019/1/16
Y1 - 2019/1/16
N2 - Before a first-in-man trial is conducted, preclinical studies are performed in animals to help characterise the safety profile of the new medicine. We propose a robust Bayesian hierarchical model to synthesise animal and human toxicity data, using scaling factors to translate doses administered to different animal species onto an equivalent human scale. After scaling doses, the parameters of dose-toxicity models intrinsic to different animal species can be interpreted on a common scale. A prior distribution is specified for each translation factor to capture uncertainty about differences between toxicity of the drug in animals and humans. Information from animals can then be leveraged to learn about the relationship between dose and risk of toxicity in a new phase I trial in humans. The model allows human dose-toxicity parameters to be exchangeable with the study-specific parameters of animal species studied so far or non-exchangeable with any of them. This leads to robust inferences, enabling the model to give greatest weight to the animal data with parameters most consistent with human parameters or discount all animal data in the case of non-exchangeability. The proposed model is illustrated using a case study and simulations. Numerical results suggest that our proposal improves the precision of estimates of the toxicity rates when animal and human data are consistent, while it discounts animal data in cases of inconsistency.
AB - Before a first-in-man trial is conducted, preclinical studies are performed in animals to help characterise the safety profile of the new medicine. We propose a robust Bayesian hierarchical model to synthesise animal and human toxicity data, using scaling factors to translate doses administered to different animal species onto an equivalent human scale. After scaling doses, the parameters of dose-toxicity models intrinsic to different animal species can be interpreted on a common scale. A prior distribution is specified for each translation factor to capture uncertainty about differences between toxicity of the drug in animals and humans. Information from animals can then be leveraged to learn about the relationship between dose and risk of toxicity in a new phase I trial in humans. The model allows human dose-toxicity parameters to be exchangeable with the study-specific parameters of animal species studied so far or non-exchangeable with any of them. This leads to robust inferences, enabling the model to give greatest weight to the animal data with parameters most consistent with human parameters or discount all animal data in the case of non-exchangeability. The proposed model is illustrated using a case study and simulations. Numerical results suggest that our proposal improves the precision of estimates of the toxicity rates when animal and human data are consistent, while it discounts animal data in cases of inconsistency.
KW - Bayesian hierarchical model
KW - historical data
KW - oncology
KW - phase I clinical trials
KW - robustness
U2 - 10.1177/0962280218820040
DO - 10.1177/0962280218820040
M3 - Journal article
JO - Statistical Methods in Medical Research
JF - Statistical Methods in Medical Research
SN - 0962-2802
ER -